Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL (clinicaltrials.gov) - Sep 17, 2026 - P2 | N=13 | Active, not recruiting | Sponsor: Dana-Farber Cancer Institute | Trial completion date: Aug 2026 ➔ Aug 2027
Trial completion date • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology
|